Referred to us by investors, ALX was preparing for their IPO and needed guidance on building a story to differentiate them from their competitor, a public company recently acquired by big pharma. ALX’s existing deck used data comparison to call out their product’s superiority but overlooked the main message of how their therapeutic approach was unique.

To better understand the CD47 field, we conducted research and interviews with the management and science teams and discovered ALX’s approach was developed on different initial research than that of their competitor. Using this insight, we chose to build the investor story around the evolution of CD47 research and highlight where ALX Oncology fits into the overall space. This allowed us to elevate their novel work and make it distinct from the competition.

“That was very different, and that is how we now introduce our story. It is very effective… investors really compliment us on the deck, the way we tell the story.” – Nathan Caffo, ALX Chief Business Officer

To learn more about this project, read our ALX Oncology case study here.